Antibodies to glutamic acid decarboxylase (GAD) have been associated with several neurological syndromes, including stiff-person syndrome, cerebellar ataxia and epilepsy. These antibodies were first described in 1988, but several controversies about GAD autoimmunity still remain. No criteria exist to establish when a neurological syndrome is pathogenically linked to GAD antibodies, often leading to the assumption that any syndrome in which these antibodies are present is immune mediated, sometimes resulting in misdiagnosis and unnecessary treatment.
Vous souhaitez en lire plus ?
Connectez-vous à votre compte ou inscrivez-vous à Neurodiem pour consulter la suite.
Vous avez déjà un compte ? S'identifier
© Springer Nature Limited 2020